Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 27, 2015 9:19 PM ET

Diversified Consumer Services

Company Overview of University of Minnesota

Company Overview

University of Minnesota is an educational institution that provides undergraduate and graduate programs. It offers courses in business administration, agriculture and life sciences, arts, medicine, engineering, mathematics, nursing and health sciences, and social services. University of Minnesota was founded in 1851 and is based in Minneapolis, Minnesota.

Minneapolis, MN 55455

United States

Founded in 1851



Key Executives for University of Minnesota

President and Board of Regents
Age: 57
Vice President of Research
Age: 63
Vice President of Health Sciences and Dean of Medical School
Chief of Staff
Vice President for University Relations
Age: 58
Compensation as of Fiscal Year 2014.

University of Minnesota Key Developments

Cellectis Plant Sciences, Inc. Signs License Agreement with the University of Minnesota

Cellectis plant sciences Inc. has announced that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide rights to use the technology covered by the patent rights of the family WO/2014/144155 entitled "Engineering Plant Genomes Using CRISPR/Cas Systems". In addition to meganucleases and TALEN (TradeMark) technology, this approach for targeted modification of plant genomes was developed by the laboratory of Professor Dan Voytas in the University of Minnesota. The technology has demonstrated results in plant genome engineering and adds to Cellectis plant sciences Inc. strong intellectual property rights in the gene editing field, in addition to meganuclease and TALENTM technologies. Similarly to meganucleases, Zinc Fingers and TALEN (TradeMark), CRISPR technology enables a number of useful tools to target specific loci in a genome and/or modulate the expression of genes. The technology is based on novel sequence-specific nucleases that can be cheaply engineered to recognize any gene of interest in a genome. Application in plants, similarly to the other gene editing technologies, could enable the development of valuable crops.

U of M Plans To Sell Midway Building

University of Minnesota (U of M) is planning to sell an office and warehouse building in St. Paul's Midway area.

RedHill Biopharma Ltd. Acquires Rights of Patented Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program

RedHill Biopharma Ltd. announced that it has entered into a license agreement with the University of Minnesota to acquire the rights to a patented technology to support the development of a commercial diagnostic test for detection of Mycobacterium avium subspecies paratuberculosis (‘MAP’) bacterium. The company’s Crohn's disease program RHB-104, currently undergoing a first Phase III study in the U.S., Canada and Israel, is based on increasing evidence supporting the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients. There is currently no validated, commercially available method of detecting the presence or absence of MAP in patients suffering from Crohn's disease and other diseases. As part of its development efforts for RHB-104, RedHill is developing, in collaboration with Quest Diagnostics, a diagnostic test to aid in detecting the presence of MAP in whole blood. The patents acquired from the University of Minnesota are intended to support the ongoing development and validation of this diagnostic test in current and future clinical studies. The company will pay the University of Minnesota a one-time upfront payment and an additional potential milestone payment for the licensed technology. A pre-submission meeting with the FDA to discuss the development path for the diagnostic test is scheduled for January 2015. Currently in a first Phase III study for the treatment of Crohn's disease (the MAP US study), RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHB-104 is based on increasing evidence supporting the hypothesis that Crohn's disease is caused by the Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. The RHB-104 formulation was originally developed by Professor Thomas Borody, a leading innovator of therapeutic approaches to treating gastrointestinal tract diseases, who also developed the original triple therapy for peptic ulcer disease associated with H. pylori. Several clinical trials were conducted with earlier formulations of RHB-104, including an Australian Phase III study conducted by Pfizer. The company has conducted several supportive studies with the current formulation of RHB-104 and a long-term population pharmacokinetic (Pop-PK) study is ongoing as part of the Phase III MAP US study. The formulation of RHB-104 is covered by several issued and pending patents.

Similar Private Companies By Industry

Company Name Region
Connecticut Center for Massage Therapy, Inc. United States
Hangers Cleaners United States
Fragomen, Del Rey, Bernsen and Loewy, LLP United States
D.M. Dykstra & Co. United States
SOS Exterminating Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact University of Minnesota, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at